{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015401","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.439560+00:00","generated_at":"2026-05-19T05:15:28.117074+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MIRA Pharma announces Ketamir-2 publication, Phase 1 progress, SKNY acquisition update","bullets":["Ketamir-2 accepted for publication in Frontiers in Pharmacology; highlights selective NMDA antagonism, no hyperlocomotion, improved oral bioavailability.","Phase 1 trial advancing as planned with dose escalation ongoing; no reported safety concerns.","Phase 2a trial in neuropathic pain expected to initiate by year-end 2025, pending regulatory clearance.","Acquisition of SKNY Pharmaceuticals (including SKNY-1 for obesity/smoking cessation) progressing; SEC filings submitted."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015401","json":"https://secwatch.observer/filing/0001641172-25-015401.json","markdown":"https://secwatch.observer/filing/0001641172-25-015401.md","text":"https://secwatch.observer/filing/0001641172-25-015401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225015401/0001641172-25-015401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225015401/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:15:28.117074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}